MAM
1000+ complaints of misleading ads on DoCA portal in 2015-16
NEW DELHI: A total of 1046 complaints have been received in the past one year between March 2015 and 31 March 2016 on the portal Grievances Against Misleading Advertisements (GAMA) set up by the Department of Consumer Affairs (DoCA).
After preliminary scrutiny of the grievances registered on the portal, the grievances are forwarded to the state government concerned or the respective central regulator as the case may be.
Of these, complaints relating to 363 were successfully resolved, 234 were rejected, 41 are in process with the Advertising Standards Council of India and 391 have been given to the regulator to intervene. In addition, 17 have been given to the Inter-Ministerial Monitoring Committee of the (DoCA).
The DoCA last year appointed the Advertising Standards Council of India as its executive arm to process complaints received on the GAMA (Grievance against Misleading Advertisements) portal.
The Inter-Ministerial Monitoring Committee which is headed by Additional Secretary in DoCA consists of members from Bureau of India Standards; the Information & Broadcasting, and Health Ministries; Press Council of India; ASCI; Food Safety and Standards Authority of India; Centre for Consumer Studies (Indian Institute of Public Administration); two representatives on rotation basis from NGOs/VCOs and Industrial/ Business/ Trade Bodies and Central Consumer Protection Council etc.
DoCA sources who told indiantelevision.com that a large number of misleading advertisements appear in various media, said the Consumer Protection Act 1986 is being amended for which the Consumer Protection Bill 2015 has been introduced in Lok Sabha. The Bill seeks to provide for a Central Consumer Protection Authority, the objective of which is to protect and enforce the rights of the consumers, to prevent unfair trade practices and to ensure that no advertisement is made for any goods or services which is misleading or deceiving or contravenes the provisions of the Act and rules made thereunder
Section 2 (1) (r) of the existing Act provides that the practice of making any statement, whether orally or in writing or by visible representation which falsely represents that the goods are of a particular standard, quality, quantity, grade, composition style or model; falsely represents that the services are of a particular standard, quality or grade, falls under unfair trade practices.
A consumer can make a complaint against unfair trade practice in a Consumer Forum established under the Act. If the complaint is upheld by a Consumer Forum, it can order for removal of the defect pointed out, replacing the goods with new goods free from any defect, issuance of corrective advertisement to neutralize the effect of misleading advertisement at the cost of the opposite party responsible for issuing such misleading dvertisement, etc.
Meanwhile, the Information and Broadcasting Ministry received six complaints in 2013 and 2014 and none in 2015 or the current year until April against private satellite television channels.
In most cases, I and B sources said the matter was referred to ASCI which had the advertisements removed while in two cases the Ministry gave a general directive to all channels.
All advertisements telecast on TV channels are regulated in accordance with the Advertising Code available on Ministry’s website mib.nic.in. Rule 7 (5) of the Advertising Code provides that no advertisement shall contain references which are likely to lead the public to infer that the product advertised or any of its ingredients has some special or miraculous or super-natural property or quality, which is difficult of being proved.
The I and B Ministry had constituted an Inter Ministerial Committee (IMC) under the chairmanship of the Additional Secretary and comprising of officers drawn from various ministries such as Consumer Affairs, Home Affairs, Law & Justice, Women & Child Development, Health & Family Welfare, External Affairs, Defence and including a representative from the ASCI, to take cognizance sou-motu or look into specific complaints regarding violation of the Programme Code and Advertising Code. The IMC functions in a recommendatory capacity.
The final decision regarding penalties and its quantum is taken on the basis of the recommendations of IMC. The Ministry generally issues warnings or advisories to comply with the Programme/Advertising Codes or asks the channels to scroll apologies on their channel. Occasionally, the channels are also taken off air either temporarily for a limited period depending on the gravity of the violation. A list showing details of action taken against TV channels for telecasting advertisements in violation of Rule 7(5) regarding misleading advertisements is at Annexure-II.
Meanwhile, the ASCI received a total of 525 complaints against misleading advertising content on the electronic media between 2013 and 2016. Rule 7(9) of the Advertising Code provides that no Advertisement which violates the Code for self-regulation in advertising, as adopted by the ASCI Mumbai for public exhibition in India, from time to time, shall be carried in the cable service.
While 187 complaints were received in 2013-2014, the number went up to 203 in 2014-2015 but fell to 135 in 2015-2016.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
